Shots:
- Repertoire & Genentech have entered into a collaboration & license agreement to identify & develop novel T cell-targeted therapies for an autoimmune disease, leveraging Repertoire’s DECODE platform
- As per the deal, Genentech will handle preclinical & clinical development along with global marketing in exchange for $35M upfront & ~$730M in development, regulatory & commercial milestones as well as tiered royalties while Repertoire will lead target discovery activities
- DECODE platform uniquely maps the entire immune synapse in pts, providing a comprehensive & in-depth understanding of the interactions between T cell receptors & their corresponding antigenic epitopes
Ref: Prnewswire | Image: Repertoire & Genentech
Related News:- Genentech Reports the FDA’s sBLA Acceptance for Gazyva to Treat Lupus Nephritis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
